219 related articles for article (PubMed ID: 31795079)
1. Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.
Nicolini A; Ferrari P; Morganti R; Carpi A
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795079
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
Cleary JM; Mamon HJ; Szymonifka J; Bueno R; Choi N; Donahue DM; Fidias PM; Gaissert HA; Jaklitsch MT; Kulke MH; Lynch TP; Mentzer SJ; Meyerhardt JA; Swanson RS; Wain J; Fuchs CS; Enzinger PC
BMC Cancer; 2016 Jul; 16():468. PubMed ID: 27412386
[TBL] [Abstract][Full Text] [Related]
6. Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.
Strasser-Weippl K; Higgins MJ; Chapman JW; Ingle JN; Sledge GW; Budd GT; Ellis MJ; Pritchard KI; Clemons MJ; Badovinac-Crnjevic T; Han L; Gelmon KA; Rabaglio M; Elliott C; Shepherd LE; Goss PE
J Natl Cancer Inst; 2018 Sep; 110(9):1003-1008. PubMed ID: 29554282
[TBL] [Abstract][Full Text] [Related]
7. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.
Touboul E; Buffat L; Belkacémi Y; Lefranc JP; Uzan S; Lhuillier P; Faivre C; Huart J; Lotz JP; Antoine M; Pène F; Blondon J; Izrael V; Laugier A; Schlienger M; Housset M
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):25-38. PubMed ID: 9989511
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer.
Jeong Y; Lee JL
Asia Pac J Clin Oncol; 2017 Jun; 13(3):204-211. PubMed ID: 27521286
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A
PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195
[TBL] [Abstract][Full Text] [Related]
10. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
Man S; Munoz R; Kerbel RS
Cancer Metastasis Rev; 2007 Dec; 26(3-4):737-47. PubMed ID: 17846863
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity.
Nicolini A; Rossi G; Ferrari P; Carpi A
Semin Cancer Biol; 2022 Feb; 79():68-82. PubMed ID: 32201368
[TBL] [Abstract][Full Text] [Related]
12. An immunotherapy schedule in endocrine-dependent metastatic breast cancer: correlation between clinical course and immunologic parameters.
Nicolini A; Carpi A; Rossi G
J Immunother; 2005; 28(3):276-9. PubMed ID: 15838385
[TBL] [Abstract][Full Text] [Related]
13. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).
Kasimir-Bauer S; Oberhoff C; Schindler AE; Seeber S
Int J Oncol; 2002 May; 20(5):1027-34. PubMed ID: 11956600
[TBL] [Abstract][Full Text] [Related]
14. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
15. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of drug resistance in human breast and ovarian cancers.
Kern DH
Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
[TBL] [Abstract][Full Text] [Related]
17. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
Nicolini A; Carpi A
Biomed Pharmacother; 2005 Jun; 59(5):253-63. PubMed ID: 15913946
[TBL] [Abstract][Full Text] [Related]
18. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
19. [Combination chemotherapy in metastatic breast cancer].
Kuten A; Lev L; Mohaliver J; Robinson E
Harefuah; 1981 Feb; 100(3):118-20. PubMed ID: 7262675
[TBL] [Abstract][Full Text] [Related]
20. Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.
Gandaglia G; Soligo M; Battaglia A; Muilwijk T; Robesti D; Mazzone E; Barletta F; Fossati N; Moschini M; Bandini M; Joniau S; Karnes RJ; Montorsi F; Briganti A
Eur Urol; 2019 May; 75(5):817-825. PubMed ID: 30409676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
